The Global R&D Centre will carry out R&D for potential new innovative medicines, and more than double AstraZeneca’s Shanghai R&D headcount to around 1,000.
News
Mission Bio launches Tapestri Platform to identify accurate cancer targets
The technology is the first-of-its-kind, detecting DNA and protein changes simultaneously.
Awards evening approaching for the Communications Team of the Year, Marketer and Sales Awards
The awards ceremony for the 2019 competition’s will be taking place on the 14th November at the Chelsea Harbour Hotel.
As AMR threat grows, GPs reduce antibiotic use
Antimicrobial resistance could cause as many as 10 million deaths per year by 2050.
Heart failure hospital admissions shoot up by 1/3
the British Heart Foundation has announced the launch a new £1million Hope for Hearts Fund, to test innovative ways of caring for people with heart failure.
“Molecular profiling” could be key to new liver disease treatments
Identifying new treatments for liver scarring is “critical” to tackling the epidemic of liver disease.
Refining blood tests could help detect heart failure
The proposed improvement could cut costs and save patients avoidable trips to their GP.
Trade association launched to ‘drive change’ for CBD regulation
The UK CBD market is worth £300m currently, and its double-digit growth each year has led to market value expectations of almost £1bn by 2025.
NIHR invests £34m into various global health research
The projects are part of the NIHR Research and Innovation for Global Health Transformation (RIGHT) programme.
Public show support for ‘rapid’ new A&E measures
Despite just one in seven of the public actually knowing what the current target in A&E is, although it has been used for 15 years.
LEO Pharma inks novel compounds deal with Ubiquigent
The companies initially entered an agreement in 2018 as part of LEO Pharma Open Innovation.
UK to be ‘transformed’ into radiotherapy research hub
The drive is supported by an additional £56 million funding from Cancer Research UK.
First patient dosed with Chiesi’s Holoclar
In 2017, NICE recommended Holoclar as an option for adults with moderate-to-severe LSCD after eye burns
PRAC cautions use of Lemtrada, Xeljanz in latest meeting
Pfizer’s Xeljanz could potentially increase the risk of blood clots.
Cosentyx ‘narrowly’ misses superiority VS Humira
AbbVie’s blockbuster Humira still holds the crown for being the world’s best selling drug.
